BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8698055)

  • 1. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
    Miyauchi T; Wahl RL
    Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
    Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
    J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.
    Zasadny KR; Wahl RL
    Radiology; 1993 Dec; 189(3):847-50. PubMed ID: 8234714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Glut-1 glucose transporter expression with.
    Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
    Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
    Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
    Christensen JD; Colby TV; Patz EF
    Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET partial volume effect correction using a modified recovery coefficient approach based on functional volume and local contrast: physical validation and clinical feasibility in oncology.
    Anouan KJ; Lelandais B; Edet-Sanson A; Ruan S; Vera P; Gardin I; Hapdey S
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):301-313. PubMed ID: 26407135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
    Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
    Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting recurrent or residual lung cancer with FDG-PET.
    Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
    J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.